According to Texas-based CDMO Matica Biotechnology, the company will provide development and manufacturing services to vaccine developer VaxDome, also based in Texas, to advance a VaxDome intranasal antiviral / vaccine candidate into clinical trials. Matica Bio says that the work will include process and analytical development as well as manufacturing of clinical trial materials, both cGMP and non-GMP
According to the announcement, the project involves VaxDome’s “unique approach to broad protection against diverse known / unknown viruses as well as lung cancer by rapid transformation of a selected influenza virus strain into a safe, intranasally delivered, antigen-agnostic antiviral / vaccine hybrid (zIFV).”
Matica Bio CEO Paul Kim commented, “VaxDome’s hybrid technology is a really fresh take on how we can treat and prevent viral infections in a wide variety of disease settings including flu. Our Texas site has the right systems, advanced cell line technologies, and specialized technical staff to take this project from early process development all the way through to manufacturing the actual batches for clinical trials.”
VaxDome CEO De-chu Christopher Tang said, “We chose Matica Bio because they can handle every step of the manufacturing process under one roof. Having development, analytical testing, and GMP production fully integrated at their Texas facility gives our team complete peace of mind as we move this candidate toward the clinic.”
Read the Matica Biotechnology press release
